Information Provided By: 
Fly News Breaks for July 26, 2016
CHE
Jul 26, 2016 | 07:28 EDT
Oppenheimer analyst Michael Wiederhorn raised his price target for Chemed to $155 from $145 after the company reported "solid" quarterly results as it continues to overcome the headwinds on the Vitas business. The analyst continues to favor Chemed and reiterates an Outperform rating on the shares as its core business suggests a return to its "historically steady growth" in 2017.
News For CHE From the Last 2 Days
There are no results for your query CHE
